Aureka Biotechnologies, a biotechnology company developing AI-powered antibody therapies, said it has raised tens of millions of U.S. dollars in a Series A funding round co-led by 5Y Capital and Qiming Venture Partners. Existing backer NRL Capital and new investors including Agentic Ventures also participated.The proceeds will be used to advance Aureka’s therapeutic pipeline toward key clinical milestones, accelerate the buildout of its intelligent closed-loop antibody design platform that integrates computational and experimental processes, and deepen collaborations with global pharmaceutical partners, the company said in a statement.Founded in 2023, Aureka combines generative AI with high-throughput biotechnology to design proteins and discover next-generation immunotherapies. Its proprietary system merges single-cell functional screening with automated yeast-based directed evolution, creating a continuous experimental data “flywheel” for its AI models. The approach enables the efficient discovery and optimization of antibodies, enhancing both speed and accuracy in developing First-in-Class and Best-in-Class therapies.Aureka said it continues to expand the functional and phenotypic precision of its data collection systems while building self-evolving design agents capable of autonomous iteration. Its multidimensional AI models can generalize across complex biological targets and mechanisms while optimizing for specific therapeutic outcomes.The company is focusing on several challenging, high-value therapeutic areas, including epitope-specific antibodies, multispecific and pH-switchable antibodies, and molecules designed for targeted endocytosis. These AI-designed antibodies are intended to offer higher safety, improved efficacy, and greater clinical differentiation, addressing unmet needs in fields such as autoimmune and metabolic diseases.Aureka has already signed strategic research collaborations with major pharmaceutical companies in the United States and Europe, working jointly on complex antibody targets and mechanisms. These partnerships have demonstrated the platform’s efficiency compared with traditional drug discovery methods, particularly in functional validation and optimization.Several of Aureka’s proprietary drug candidates are now approaching preclinical candidate (PCC) or pre-investigational new drug (pre-IND) stages, according to the company.Over the past two years, Aureka has achieved commercial revenue in the millions of U.S. dollars and plans to expand co-development and joint pipeline opportunities globally.Dr. Wei’an Zhao, founder and CEO of Aureka Biotechnologies, said the company aims to redefine antibody discovery. “Antibodies are not just discovered—they can be designed,” Zhao said. “Our goal is to create autonomous intelligent agents that participate in design and experimentation, forming a self-improving closed loop that continuously evolves.”Investors praised Aureka’s data-driven approach. “Aureka’s high-throughput data generation and AI integration represent rare value in today’s macromolecular drug discovery,” said Jingtian Xu, Partner at 5Y Capital.Qiming Venture Partners’ Managing Partner Xubo Hu added: “The company has built an efficient, scalable drug discovery system that can shorten development cycles and lower costs. We believe it could become part of the new infrastructure of biopharma innovation.”更多精彩内容，关注钛媒体微信号（ID：taimeiti），或者下载钛媒体App